ClinicalTrials.gg
Not yet recruitingNCT06871644Updated Mar 12, 2025

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

An interventional study of T cell injection targeting CD7 chimeric antigen receptor in Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 82 studies in Scleroderma, Systemic with a site in China — 64 open to participants now, 69 under way, 4 of them phase 3. Scleroderma, Systemic · China.

Planned enrollment
41st of 77
18 · median 20
Started
2025
with 28 others
No phase
15 of 82
14 open now
Primary completion
2026-03
later than 13 of 68 live
Registered
38th of 82
by date
Lead sponsor
4 of 82
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Among the 82 studies in Scleroderma, Systemic with a site in China, this one is the 41st largest by planned enrollment of the 77 interventional ones that give a count, is one of 29 that started in 2025, is one of 15 with no phase, reaches primary completion later than 13 of the 68 other live ones, and was the 38th registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

64 of the 82 studies in Scleroderma, Systemic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 146 Scleroderma, Systemic studies recruiting now, 84 (58%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Scleroderma, Systemic with a site in China, or all of them as a file.
02

Study summary

The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.

Read the detailed description

Subjects who meet the inclusion/exclusion criteria will be entered into 3 groups in sequential order for a single dose. The dose-escalation study utilizes a "3+3" design, i.e., 3-6 subjects in each group will complete a single dose.

After the last subject in each dose group completes a dose-limiting toxicity (DLT) assessment window of 28 days after the single dose, enrollment in the next dose group can begin.

When 1 DLT occurs in 3 subjects in a dose group, 3 additional subjects are required in the same dose group (up to 6 subjects in that dose group have completed DLT assessment): if no DLT occurs in the 3 additional subjects, continue the dose escalation; if 1 of the 3 additional subjects develops a DLT, stop the dose escalation; if >1 of the 3 additional subjects DLT occurs, the dose escalation is stopped and a one-dose reduction is required to continue enrolling 3 more subjects for DLT assessment.

03

Conditions studied

  • Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed relapsing/ systemic sclerosis that has failed treatment with at least two and/or biologic agents.

Bone marrow and coagulation function, liver and kidney function, cardiopulmonary function are satisfied No serious mental disorders

Exclusion criteria

Exclusion Criteria:

  • other than AID disease within 5 years prior to screening surface antigen (HBsAg) positive, AIDS, syphilis and other virus positive persons Severe heart disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    T cell injection targeting CD7 chimeric antigen receptor

    CD7 CAR-T cell therapy Subjects meeting the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108, and 2×108 CAR-T groups in sequential order, and will be administered once

    Biological: T cell injection targeting CD7 chimeric antigen receptor

Interventions

06

What researchers measure

Primary outcomes

  1. adverse events

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: About 1 year

Secondary outcomes

  1. (Cmax)

    Maximum concentration of CD7 CAR-T cells expanded in peripheral blood after drug administration

    Time frame: About 1 year

  2. (Tmax)

    Time to maximum concentration

    Time frame: About 1 year

  3. AUC0-28d

    Area under the curve at 28 days

    Time frame: About 28 days

  4. AUC0-90d

    Area under the curve at 90 days

    Time frame: About 90 days

  5. Disease remission rate

    Rate of decline from baseline in the American College of Rheumatology Composite Response Index (ACR-CRISS)

    Time frame: About 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Research details

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.

Of 101 interventional studies with no phase under Scleroderma, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 12, 2025
StartEst.
Mar 18, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06871644
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Mar 18, 2025 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 12, 2025

Study contacts

zhu chen, doctor
Contact
doczchen@ustc.edu.cn
0551-62283843
qian wang, bachelor
Contact
wangqian528@mail.ustc.edu.cn
+86 15155193878
zhu chen, doctor
principal investigator · The First Hospital Affiliated to the University of Science and Technology of China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD7 CAR T Cells PA3-17

Start the discussion